BUZZ-Astria rises on FDA's orphan drug tag for its genetic disorder treatment
Shares of drug developer Astria Therapeuticsrise about 3% to $11.45Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodemaAngiodema causes swelling of arms, face, legs and intestinal tractOrphan drug tag based on early-to-mid-stage trial, in which drug showed reduced monthly swelling attack rates by 90% to 96% when dosed once or twice over 6 monthsCo expects to get additional results from trial in Q4 and progress navenibart into late-stage trial initiating in Q1 2025Including session’s move, stock up ~47.3% YTD
Shares of drug developer Astria Therapeutics (ATXS.O) rise about 3% to $11.45
Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodema
Angiodema causes swelling of arms, face, legs and intestinal tract
Orphan drug tag based on early-to-mid-stage trial, in which drug showed reduced monthly swelling attack rates by 90% to 96% when dosed once or twice over 6 months
Co expects to get additional results from trial in Q4 and progress navenibart into late-stage trial initiating in Q1 2025
Including session’s move, stock up ~47.3% YTD
